Sofosbuvir

CHEMBL1259059 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

529.5 g/mol

LogP

1.0

Phase

4

A cornerstone of modern hepatitis C treatment, this once-daily antiviral blocks a key enzyme the hepatitis C virus needs to copy itself. When combined with other antivirals, it achieves cure rates above 95% in most patients after just 8 to 12 weeks of treatment, with minimal side effects.

Moleküler Ağırlık

529,5000 g/mol

LogP

1,00

TPSA

153,00 Å²

Lipinski RO5

Başarısız

Terapötik Alanlar

Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Hypertension HIV/AIDS Hepatitis C Heart Failure Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1

InChI

InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1

Molecular Formula

C22H29FN3O9P

HBD / HBA

3 / 11

Döndürülebilir Bağlar

11

Ağır Atomlar

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A cornerstone of modern hepatitis C treatment, this once-daily antiviral blocks a key enzyme the hepatitis C virus needs to copy itself. When combined with other antivirals, it achieves cure rates above 95% in most patients after just 8 to 12 weeks of treatment, with minimal side effects.

Yes, Sofosbuvir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1259059. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 45375808. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Sofosbuvir PillFYI'da

Yapı

Hızlı Veriler

Formül: C22H29FN3O9P
Eş Anlamlılar: 8

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.